Plasma HS Code Analysis (2026)

The primary HS code for Plasma is 30021290, which pertains to human blood plasma. Tariff rates for this code vary across countries:

• United States: The Most Favored Nation (MFN) tariff rate for HS code 30021290 is "Free," indicating no import duties are applied.

• European Union (EU): Member countries, including Germany and Finland, apply an MFN tariff rate of 0.00% for HS code 30021290, allowing duty-free importation.

• United Kingdom: Similarly, the UK imposes an MFN tariff rate of 0.00% on imports under this code.

• Singapore: As a member of the Association of Southeast Asian Nations (ASEAN), Singapore generally offers low or zero tariffs on pharmaceutical products, including Plasma.

• South Africa: As a member of the Southern African Customs Union (SACU), South Africa typically applies low or zero tariffs on essential medicines, including Plasma.

• Guyana, Sudan, Madagascar: Specific tariff information for these countries is not readily available. However, many developing nations offer reduced or zero tariffs on essential medicines to ensure accessibility.

It's important to note that many countries provide exemptions or reduced tariffs for essential medicines, including Plasma, to promote public health. Importers should consult the respective national customs authorities or the World Trade Organization (WTO) tariff databases for the most current and detailed information.

Plasma is primarily classified under HS code 30021290, designated for human blood plasma. However, classification disputes can arise, particularly when distinguishing between HS codes 3003 and 3004:

• HS Code 3003: This code covers "Medicaments consisting of two or more constituents mixed together for therapeutic or prophylactic uses, not put up in measured doses or forms."

• HS Code 3004: This code pertains to "Medicaments consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses or forms."

Misclassification can occur if Plasma products are incorrectly categorized under these codes, leading to potential customs penalties, including fines and delays in shipment clearance. To mitigate these risks, it's crucial to ensure accurate classification based on the product's specific characteristics and intended use. Consulting the World Customs Organization (WCO) guidelines and national customs rulings can provide clarity on proper classification.

Pharmacopoeial standards for Plasma are established to ensure product quality, safety, and efficacy. The United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP) provide monographs detailing these standards.

• Purity and Assay Requirements: Monographs specify acceptable purity levels and assay methods to confirm the potency of Plasma. These include tests for identity, potency, and the presence of impurities.

• Dissolution Testing: While dissolution testing is more commonly associated with solid oral dosage forms, the principles of ensuring consistent bioavailability apply to Plasma products. The USP provides guidelines on dissolution procedures, emphasizing the importance of method development and validation.

• Stability Testing: Stability testing for Plasma products is conducted in accordance with the International Council for Harmonisation (ICH) guidelines, considering different climatic zones (ICH Zones I–IV). These tests assess the product's shelf life and storage conditions to maintain efficacy and safety over time.

Adherence to these pharmacopoeial standards is essential for regulatory compliance and to ensure the therapeutic effectiveness of Plasma products.